CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
2 hedge funds and large institutions have $474K invested in CTI BioPharma Corp. (DE) Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 131 closing their positions.
350% more call options, than puts
Call options by funds: $9K | Put options by funds: $2K
98% less funds holding
Funds holding: 133 → 2 (-131)
100% less capital invested
Capital invested by funds: $475M → $474K (-$475M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 131
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$52.2M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$37.6M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$37M |
| 4 |
BlackRock
New York
|
-$29.8M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$27.4M |
CTIC Hedge Fund Activity: Q2 2023 in Review
2 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q2 2023, worth a combined $474K — down 100% from $475M a quarter earlier.
Sellers outnumbered buyers: 131 funds closed out of CTIC and 0 opened new positions — a net loss of 131 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was State Street, exiting entirely with an estimated $52.2M sold.
- 2 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q2 2023, down from 133 in Q1 2023.
- Funds reported $474K of CTI BioPharma Corp. (DE) Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q2 2023 and 131 closed out, a net change of -131 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q2 2023 was State Street, an estimated $52.2M sold.
Based on aggregated 13F filings for Q2 2023.